N-benzyladriamycin-14-valerate (AD 198): A non-cardiotoxic anthracycline that is cardioprotective through PKC-ε activation

Journal of Pharmacology and Experimental Therapeutics

Volumn 323, Issue 2, 2007, Pages 658-664

  Hofmann, Polly A ^a   Israel, Mervyn ^a   Koseki, Yoshihiro ^a   Laskin, Jeffrey ^c   Gray, Joshua ^c   Janik, Aleksandra ^a   Sweatman, Trevor W ^a,b   Lothstein, Leonard ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; N BENZYLDOXORUBICIN 14 VALERATE; PROTEIN KINASE C EPSILON; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG DOSE INCREASE; ENZYME ACTIVATION; FEMALE; HEART INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE; HYPOXIA; LD 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANIMALS; DOXORUBICIN; ENZYME ACTIVATION; FEMALE; HEART; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MICE; MICE, INBRED C57BL; PROTEIN KINASE C-EPSILON; RATS; RATS, WISTAR; VENTRICULAR FUNCTION, LEFT;

EID: 35548973458     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.126110     Document Type: Article

References (41)

1. Baines CP, Zhang J, Wang GW, Zheng YT, Xiu JX, Cardwell EM, Bolli R, and Ping P (2002) Mitochondrial PKCepsilon and MAPK form signaling modules in the murine heart: enhanced mitochondrial PKCepsilon-MAPK interactions and differential MAPK activation in PKCepsilon-induced cardioprotection. Circ Res 90:390-397.
2. Barrett CM, Roaten JB, Lewis FL, Sweatman TW, Israel M, and Lothstein L (2002) Drug-induced modulation of protein kinase C (PKC) correlates with circumvention of Bcl-2-mediated inhibition of apoptosis Mol Cancer Ther 1:469-481.
3. Bertazzoli C, Bellini O, Magrini U, and Tosana MG (1979) Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse. Cancer Treat Rep 63:1877-1883.
4. Bilyeu JD, Panta GR, Cavin LG, Barrett CM, Turner EJ, Sweatman TW, Israel M, Lothstein L, and Arsura M (2004) Circumvention of nuclear factor kappaB-induced chemoresistance by cytoplasmic-targeted anthracyclines. Mol Pharmacol 65:1038-1047.
5. Binaschi M, Bigioni M, Cipollone A, Rossi C, Goso C, Maggi CA, Capranico G, and Animati F (2001) Anthracyclines: selected new developments. Curr Med Chem Anticancer Agents 1:113-130.
6. Bolli R (2000) The late phase of preconditioning. Circ Res 87:972-983.
7. Burke TG, Israel M, Seshadri R, and Doroshow JH (1989) A fluorescence study examining how 14-valerate side chain substitution modulates anthracycline binding to small unilamellar phospholipid vesicles. Biochim Biophys Acta 982:123-130.
8. Cohen MV, Baines CP, and Downey JM (2000) Ischemic preconditioning: from adenosine receptor to kATP channel. Annu Rev Physiol 62:79-109.
9. Frishman WH, Sung HM, Yee HCM, Liu LL, Keefe D, Einzig AI, and Dutcher J (1996) Cardiovascular toxicity with cancer chemotherapy. Curr Probl Cardiol 21:225-288.
10. Gray MO, Karliner JS, and Mochly-Rosen D (1997) A selective epsilon-protein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death. J Biol Chem 272:30945-30951.
11. Gysembergh A, Zakaroff-Girard A, Loufoua J, Meunier L, Andre-Fouet X, Lagarde M, Prigent AF, and Ovize M (2000) Brief preconditioning ischemia alters diacylglycerol content and composition in rabbit heart. Basic Res Cardiol 95:457-465.
12. 2+ overload in isolated rat hearts. Cardiovasc Drugs Ther 14:489-495.
13. Jensen BV, Skovsgaard T, and Nielsen SL (2002) Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 13:699-709.
14. Jin ZQ, Zhou HZ, Zhu P, Honbo N, Mochly-Rosen D, Messing RO, Goetzl EJ, Karliner JS, and Gray MO (2002) Cardioprotection mediated by sphingosine-1-phosphate and ganglioside GM-1 in wild-type and PKC epsilon knockout mouse hearts. Am J Physiol Heart Circ Physiol 282:H1970-H1977.
15. Kawamura S, Yoshida K, Miura T, Mizukami Y, and Matsuzaki M (1998) Ischemic preconditioning translocates PKC-delta and -epsilon, which mediate functional protection in isolated rat heart. Am J Physiol 275:H2266-H2271.
16. Lester JW, Gannaway KF, Reardon RA, Koon LD, and Hofmann PA (1996) Effects of adenosine and protein kinase C stimulation on mechanical properties of rat cardiac myocytes. Am J Physiol Heart Circ Physiol 271:H1778-H1785.
17. Liu GS, Cohen MV, Mochly-Rosen D, and Downey JM (1999) Protein kinase Cepsilon is responsible for the protection of preconditioning in rabbit cardiomyocytes. J Mol Cell Cardiol 31:1937-1948.
18. Liu Q and Hofmann PA (2003) Modulation of protein phosphatase 2a by adenosine A1 receptors in cardiomyocytes: role for p38 MAPK. Am J Physiol Heart Circ Physiol 285:H97-H103.
19. Lothstein L, Israel M, and Sweatman TW (2001) Anthracycline drug targeting: cytoplasmic versus nuclear-a fork in the road. Drug Resist Update 4:169-177.
20. Lothstein L, Rodrigues PJ, Sweatman TW, and Israel M (1998) Intracellular activity, distribution, and metabolism of N-benzyladriamycin-14-valerate (AD 198) are modulated by changes in 14-O-acyl chain length. Anti-Cancer Drugs 9:58-66.
21. 2+ influx. Anticancer Drugs 17:495-502.
22. Lothstein L, Sweatman TW, Dockter ME, and Israel M (1992) Resistance to N-benzyladriamycin-14-valerate in mouse J774.2 cells: P-glycoprotein expression without reduced N-benzyladriamycin-14-valerate accumulation. Cancer Res 52:3409-3417.
23. Minotti G, Licata S, Saponiero A, Menna P, Calafiore AM, Di Giammarco G, Liberi G, Animati F, Cipollone A, Manzini S, et al. (2000) Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite. Chem Res Toxicol 13:1336-1341.
24. Murry CE, Jennings RB, and Reimer KA (1986) Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74:1124-1136.
25. Oldenburg O, Cohen M, Yellon D, and Downey J (2002) Mitochondrial K(ATP) channels: role in cardioprotection. Cardiovasc Res 55:429-437.
26. Ping P, Zhang J, Cao X, Li RCX, Kong D, Tang X-L, Qiu Y, Manchikalapudi S, Auchampach JA, Black RG, et al. (1999) PKC-dependent activation of p44/p42 MAPKs during myocardial ischemia-reperfusion in conscious rabbits. Am J Physiol 276:H1468-H1481.
27. Ping P, Zhang J, Pierce WM Jr, and Bolli R (2001) Functional proteomic analysis of protein kinase C-e signaling complexes in the normal heart and during cardioprotection. Circ Res 88:59-62.
28. Pyle WG, Lester JW, and Hofmann PA (2001) Effects of kappa-opioid receptor activation on myocardium. Am J Physiol Heart Circ Physiol 281:H669-H678.
29. Pyle WG, Smith TD, and Hofmann PA (2000) Cardioprotection with kappa-opioid receptor stimulation is associated with a slowing of cross-bridge cycling. Am J Physiol Heart Circ Physiol 279:H1941-H1948.
30. Roaten JB, Kazanietz MG, Caloca MJ, Bertics PJ, Wiepz GJ, Parrill AL, Rodrigues PJ, Lothstein L, Israel M, and Sweatman TW (2002) Protein kinase C inhibition by N-benzyladriamycin-14-valerate (AD 198): structural requirements, isoform specificity and interaction with the C1-regulatory domain Mol Cancer Ther 1:483-492.
31. Roaten JB, Kazanietz MG, Sweatman TW, Lothstein L, Israel M, and Parrill AL (2001) Molecular models of N-benzyladriamycin-14-valerate (AD 198) in complex with the phorbol ester-binding C1 domain of protein kinase C-δ. J Med Chem 44:1028-1034.
32. Saeki K, Obi I, Ogiku N, Shigekawa M, Imagawa T, and Matsumoto T (2002) Doxorubicin directly binds to the cardiac-type ryanodine receptor. Life Sci 70:2377-2389.
33. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792.
34. Schultz PN, Beck ML, Stava C, and Vassilopoulou-Sellin R (2003) Health profiles in 5836 long-term cancer survivors. Int J Cancer 104:488-495.
35. Speyer J and Wasserheit C (1998) Strategies for reduction of anthracycline cardiac toxicity. Semin Oncol 25:525-537.
36. Swain SM, Whaley FS, and Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869-2879.
37. Sweatman TW and Israel M (1996) Anthracyclines, in Cancer Therapeutics: Experimental and Clinical Agents (Teicher BA ed) pp 113-136, Humana Press Inc, Totowa, NJ.
38. Yaguchi Y, Satoh H, Wakahara N, Katoh H, Uehara A, Terada H, Fujise Y, and Hayashi H (2003) Protective effects of hydrogen peroxide against ischemia/reperfusion injury in perfused rat hearts. Circ J 67:253-258.
39. Yang C and Kazanietz MG (2003) Divergence and complexities in DAG signaling: looking beyond PKC. Trends Pharmacol Sci 24:602-608.
40. Yue Y, Qin Q, Cohen MV, Downey JM, and Critz SD (2002) The relative order of mK(ATP) channels, free radicals and p38 MAPK in preconditioning's protective pathway in rat heart. Cardiovasc Res 55:681-689.
41. Zhou M, Diwu Z, Panchuk-Voloshina N, and Haugland RP (1997) A stable nonfluorescent derivative of resorufin for the fluorometric determination of trace hydrogen peroxide: applications in detecting the activity of phagocyte NADPH oxidase and other oxidases. Anal Biochem 253:162-168.